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Insulin stimulates glucose transport by promoting exocytosis of
the glucose transporter Glut4 (refs 1, 2). The dynamic processes
involved in the trafficking of Glut4-containing vesicles, and in
their targeting, docking and fusion at the plasma membrane, as
well as the signalling processes that govern these events, are not
well understood. We recently described tyrosine-phosphoryl-
ation events restricted to subdomains of the plasma membrane
that result in activation of the G protein TC10 (refs 3, 4). Here we
show that TC10 interacts with one of the components of the
exocyst complex, Exo70. Exo70 translocates to the plasma mem-
brane in response to insulin through the activation of TC10,
where it assembles a multiprotein complex that includes Sec6
and Sec8. Overexpression of an Exo70 mutant blocked insulin-
stimulated glucose uptake, but not the trafficking of Glut4 to the
plasma membrane. However, this mutant did block the extra-
cellular exposure of the Glut4 protein. So, the exocyst might have
a crucial role in the targeting of the Glut4 vesicle to the plasma
membrane, perhaps directing the vesicle to the precise site of
fusion.
To search for potential effectors of TC10 that have a role in
insulin-stimulated glucose transport, we screened a yeast two-
hybrid complementary-DNA library derived from 3T3L1 adipo-
cytes with a constitutively active mutant form of human TC10a5,
and identified two clones encoding the full-length sequence of
Exo70, a component of the exocyst complex, which has been
implicated in the tethering or docking of secretory vesicles6,7. To
explore the specificity of the interaction of TC10 with Exo70, we co-
transfected 293T cells with myc-tagged Exo70 and haemagglutinin
(HA)-tagged, constitutively active forms of mouse TC10a, Rho1,
Rac1 or Cdc42 cDNAs8–11 (Fig. 1a). Exo70 could be co-precipitated
with TC10, but not with Rho, Rac or Cdc42, indicating that its
interaction with TC10 is specific. TC10b could also be co-precipi-
tated with Exo70 (data not shown). To evaluate whether Exo70 is a
potential effector of TC10, we incubated lysates derived from cells
expressing different forms of HA-tagged TC10 with a glutathione
S-transferase (GST)–Exo70 fusion protein, to examine binding
in vitro (Fig. 1b). Exo70 bound to the constitutively active mutant
TC10a(Q67L), but not to the dominant-interfering TC10a(T23N).
Identical results were obtained with the corresponding mutants
TC10b(T25N) and TC10b(Q69L) (data not shown). To confirm that
the interaction of TC10 with Exo70 was GTP-dependent, lysates
expressing TC10 were loaded with GDP or a non-hydrolysable form
of GTP (GTPgS) in vitro, and incubated with GST–Exo70. Exo70
bound weakly to the GDP-bound form of TC10, and strongly to the
GTP-bound, activated state of the protein. These data show that
Exo70 interacts with TC10 in a GTP-dependent manner.
To study the function of Exo70 in glucose transport, we sought to
map its TC10 binding site through a series of deletion mutants.
Exo70 has only one putative protein–protein interaction region, a
coiled-coil domain in the amino terminus (Fig. 1c). We deleted
amino acids 1–384 of Exo70, and also prepared constructs expres-
sing only amino acids 1–384, 1–99 or 100–384, and evaluated the
ability of the mutants to bind constitutively active TC10a(Q67L) in
a co-precipitation experiment. Whereas wild-type Exo70 (Exo70-
WT) bound to TC10, Exo70(385–653) (Exo70-C) did not. More-
over, an Exo70 fragment containing only amino acids 1–384
(Exo70-N) bound to TC10, whereas Exo70 containing amino
acids 1–99, which comprised the coiled-coil domain, bound weakly,
and Exo70 containing residues 100–384 also bound weakly. These
data indicate that amino acids 1–384 of Exo70 are both necessary and
sufficient for binding to TC10, but that this interaction requires more
than the coiled-coil domain (Fig. 1d and Supplementary Fig. 1).
We analysed the intracellular localization of Exo70 by immuno-
histochemistry, and evaluated its potential regulation by insulin and
TC10. 3T3L1 adipocytes were transfected with myc–Exo70 plus or
minus TC10 and its mutants. As shown in Fig. 2a, b, myc–Exo70 was
distributed diffusely throughout the intracellular region. Co-
expression of TC10 or its inactive mutant TC10(T23N) did not
influence the localization of overexpressed myc–Exo70. By contrast,
Exo70 was localized at the plasma membrane when co-expressed
with the constitutively active mutant TC10(Q67L), indicating that
TC10 activation stimulates the translocation of Exo70. We also
examined whether the amino-terminal fragment of Exo70 (Exo70-
N) translocated to the plasma membrane after expression of active
TC10. Unlike the wild-type form of the protein, this fragment did
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not translocate to the membrane when co-expressed with active
TC10, despite the fact that it can bind to the protein in vitro or
after co-expression in 293T cells (Fig. 1d). These data suggest that
the carboxy-terminal sequences in Exo70 are required for the
movement of the protein in adipocytes, possibly owing to an
interaction with another protein.
The translocation of Exo70 to the plasma membrane by activated
TC10 suggested that insulin might induce a similar redistribution of
the protein. Following transfection with myc–Exo70, cells were
stimulated with insulin, and the localization of the protein was
examined by immunohistochemistry. Insulin stimulation resulted
in the translocation of Exo70 to the plasma membrane. This event
was blocked by the co-transfection of cells with the inactive mutant
TC10(T23N) (Fig. 2c, d). By contrast, co-expression with the wild-
type or constitutively active mutant of TC10 did not block the effect
of insulin (data not shown). Interestingly, as observed above with
the overexpression of active TC10, insulin failed to stimulate the
translocation of the amino-terminal fragment of Exo70 to the
plasma membrane.
The observation that insulin can recruit Exo70 to the plasma
membrane by way of TC10 suggests that insulin might promote the
assembly of the exocyst complex through an interaction between
TC10 and Exo70. The exocyst complex is thought to assemble before
the fusion of secretory vesicles with the plasma membrane12–14. This
complex includes the proteins Sec6 and Sec8, which have been
shown to regulate the late stage of exocytosis in MDCK cells15,16.
Unfortunately, antibodies to Sec6 and Sec8 could not be used for
immunohistochemistry. So, to evaluate the localization of these
endogenous proteins, we fractionated cell lysates derived from
3T3L1 adipocytes stimulated with or without insulin. Sec6 and
Sec8 were found in cytosolic and low-density microsomal (LDM)
fractions, with a small amount found in the plasma-membrane
fraction. Treatment of cells with insulin reduced the appearance of
the two proteins in the cytoplasm and low-density microsomes,
with a corresponding increase in the plasma-membrane fraction
(Fig. 3a).
We also evaluated whether Exo70 formed a complex with Sec6
and Sec8. As shown in Fig. 3b, endogenous Sec6 bound to Sec8, as
assayed by co-precipitation. This interaction was insulin-indepen-
Figure 1 Exo70 interacts with activated TC10. a, Exo70 specifically interacts with TC10.
293T cells were co-transfected with myc–Exo70 and HA-tagged, constitutively active
forms of TC10a(Q67L), RhoA(G14V), Rac1(G12V) and Cdc42(Q61L). Lysates were
immunoprecipitated (IP) with an anti-myc antibody, followed by blotting with anti-HA
antibody. b, Exo70 interacts with TC10 in a GTP-dependent manner. 293T cells were
transfected with HA-tagged wild-type TC10a, its constitutively active Q67L mutant, or its
inactive T23N mutant. Cell lysates were preincubated with either 100 mM GTPgS or 1 mM
GDP, and then incubated with glutathione-Sepharose-bound GST–Exo70. Precipitates
were analysed by immunoblot analysis with anti-HA antibody. Identical results were
obtained with TC10b (data not shown). c, Schematic of Exo70 and its deletion mutants.
cc, coiled-coil. d, Interaction of TC10 with Exo70 mutants. 293T cells were co-transfected
with HA–TC10a(Q67L) and myc-tagged wild-type Exo70 or mutants containing amino
acids 1–384 (Exo70-N), 385–653 (Exo70-C), 1–99, 100–384 or empty vector. Lysates
were immunoprecipitated with anti-myc antibody, and immunopellets were analysed by
blotting with anti-HA antibody.
Figure 2 Exo70 is translocated to the plasma membrane by insulin. a, Overexpression of
constitutively active TC10(Q75L) recruits Exo70 to the plasma membrane (PM). 3T3L1
adipocytes were co-transfected with myc–Exo70-WT or myc–Exo70-N with vector only,
HA-tagged wild-type TC10, or its Q75L or T31N mutants. Cells were fixed and stained
with anti-myc polyclonal antibody to detect myc–Exo70, and with anti-HA monoclonal
antibody to detect HA–TC10, followed by Alexa594 goat anti-rabbit IgG and Alexa488 goat
anti-mouse IgG. Fluorescence was visualized by confocal laser scanning microscopy.
Images represent four independent determinations. b, d, Graphical representation of data
from three independent experiments. *Significant difference, P , 0.0001. c, Exo70
translocates to the plasma membrane in response to insulin. 3T3L1 adipocytes were
electroporated with myc–Exo70-WT or myc–Exo70-N with or without HA–TC10(T31N),
serum-starved, and treated with or without insulin for 5 min. Cells were fixed and stained
with anti-myc antibody followed by Alexa594 goat anti-mouse IgG.
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dent. Moreover, both wild-type Exo70 and its amino-terminal
fragment bound to endogenous Sec8 (Fig. 3c, d). Interestingly,
whereas the amino-terminal region of Exo70 bound to Sec8, a
fragment of the protein containing only amino acids 385–653 did
not (data not shown). So, Exo70 appears to exist in a preformed
complex with Sec6 and Sec8, through an interaction in the amino-
terminal region of Exo70. This multiprotein complex is then
translocated to the plasma membrane in response to insulin.
As the amino-terminal fragment of Exo70 fails to translocate to
the plasma membrane in response to insulin or active TC10, this
mutant form of the protein might also block the assembly of the
exocyst complex at the cell surface. Cells were transfected with the
myc-tagged wild-type or amino-terminal fragment of Exo70
(Fig. 3e), treated with insulin, and fractionated as detailed above.
As determined by immunohistochemical analysis (Fig. 2), insulin
stimulated the translocation of wild-type Exo70 to the plasma
membrane. However, the amino-terminal fragment remained
mainly in the cytoplasm, and the localization of this protein was
not influenced by insulin. Sec8 also translocated to the membrane
in response to insulin in cells that expressed wild-type Exo70.
However, expression of the mutant form of the protein blocked
the translocation of endogenous Sec8. These data indicate that the
amino-terminal fragment of Exo70 can act as a dominant-negative
mutant, presumably blocking the insulin-stimulated assembly of
the exocyst complex at the plasma membrane.
The exocyst complex is thought to have an important role in
targeted exocytosis. To evaluate whether the interaction between
TC10 and Exo70 is involved in Glut4 vesicle trafficking, we over-
expressed Exo70 and its mutants in 3T3L1 adipocytes by electro-
poration, and assayed 2-deoxyglucose uptake17 (Fig. 4a). In cells
transfected with an empty vector, insulin produced a fivefold
increase in 2-deoxyglucose uptake. Overexpression of wild-type
Exo70 led to a 48% increase in insulin-stimulated glucose uptake
over that observed in cells transfected with an empty vector,
although basal activity was not significantly changed. By contrast,
the amino-terminal fragment of Exo70, which blocks the assembly
of the exocyst complex, produced a 40% inhibition of insulin-
stimulated transport compared with control, although basal activity
was again unaffected. In these experiments, less than 50% of the cells
were transfected by the electroporation method, indicating that
Figure 3 Components of the exocyst complex translocate to the plasma membrane in
response to insulin. a, Sec6 or Sec8 translocate to the plasma membrane in response to
insulin stimulation. After insulin stimulation, cells were placed on ice and washed three
times with ice-cold PBS. Membrane fractionation was carried out using 3T3L1 adipocytes
as reported29, and endogenous Sec6 and Sec8 were detected by monoclonal antibodies.
b, Sec8 interacts with Sec6. The cell lysates from 3T3L1 adipocytes were incubated with
a Sec8 monoclonal antibody and blotted with a Sec6 antibody. c, Sec8 and Exo70
interact. 3T3L1 adipocytes were transfected with myc–Exo70. Cells were stimulated with
100 nM insulin for 10 min. Cell lysates were incubated with a Sec8 monoclonal antibody
and blotted with an anti-myc polyclonal antibody. d, Sec8 interacts with Exo70-WT and
Exo70-N. Lysates were prepared as described in c from 3T3L1 adipocytes transfected
with myc–Exo70-WT or myc–Exo70-N. e, Exo70-N blocks membrane translocation of
Sec8. Membrane fractionation was carried out using 3T3L1 adipocytes transfected with
myc–Exo70-WT and myc–Exo70-N after insulin stimulation. Endogenous Sec8 and
caveolin-1 were detected by western blotting using the plasma-membrane fraction. The
means (and standard deviations) of three independent determinations are shown in
graphical form. *Significant difference, P , 0.005.
Figure 4 Exo70 plays a crucial role in Glut4 vesicle targeting. a, Differentiated 3T3L1
adipocytes were transfected with Exo70-WT or Exo70-N. The cells were left untreated or
were stimulated with 100 nM insulin for 30 min. The rate of [14C]2-deoxyglucose (2-DG)
uptake was determined. Cells were transfected with an efficiency of approximately 50%.
Results are expressed as the mean ^ s.d. of five separate experiments. *Significant
difference, P , 0.01. b, Number of Glut4–eGFP transfected cells with visually detectable
plasma-membrane rim fluorescence. The numbers of Glut4–eGFP-transfected cells
displaying visually detectable eGFP rim fluorescence are plotted. c, Exo70-N does not
affect HA–Glut4–eGFP translocation, but blocks its extracellular exposure. 3T3L1
adipocytes were co-electroporated with HA–Glut4–eGFP plus vector alone, myc-tagged
Exo70-WT or Exo70-N. Cells were serum-starved, treated with or without insulin for
30 min, fixed, and stained with an anti-HA monoclonal antibody followed by Alexa594 goat
anti-mouse IgG to detect cells that expressed HA–Glut4 at the surface. Fluorescence
was visualized by confocal laser scanning microscopy. Images represent three
independent determinations. d, Percentage of the HA rim positive staining cells among
the HA–Glut4–GFP-transfected cells was quantified. Fifty cells that showed translocation
of eGFP were scored for visually detectable HA rim fluorescence before and after
treatment with insulin for 30 min. These data were obtained by blind counting of
more than 50 cells from three independent experiments. *Significant difference,
P , 0.0001.
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most of the insulin-stimulated glucose transport was blocked by
overexpression of the Exo70-N mutant.
As mentioned above, insulin-stimulated glucose transport results
from the translocation of the Glut4 protein to the cell surface. So, we
next evaluated the effect of Exo70 on the translocation of a Glut4–
enhanced green fluorescent protein (eGFP) fusion protein in 3T3L1
adipocytes. Cells were co-transfected with Glut4–eGFP and with
wild-type or mutant forms of Exo70. Insulin stimulated the trans-
location of Glut4–eGFP in 90% of the cells transfected with vector
alone, as detected by increased rim fluorescence. Co-expression
with wild-type Exo70 had no impact on basal or insulin-stimulated
translocation. Interestingly, co-expression with the amino-terminal
fragment of Exo70 was also without effect on Glut4–eGFP trans-
location, despite the clear inhibition of glucose transport observed
by overexpression of this mutant (Fig. 4b).
The inhibition of insulin-stimulated glucose uptake in the face of
no effect on Glut4 translocation by the Exo70 mutant indicated that
the protein might influence the targeting or docking of Glut4 to the
plasma membrane, rather than the translocation process. To explore
this possibility in more detail, we co-expressed the Exo70 mutants
with a Glut4–GFP construct that was HA-tagged in its first extra-
cellular loop18 (Fig. 4c). This double-tagged form of Glut4 can
be detected by the fluorescence of GFP, and simultaneously
by immunodetection of the HA tag at the cell surface in non-
permeabilized cells, thus representing a method to evaluate both the
translocation and extracellular exposure of Glut4 (ref. 18). In the
absence of insulin, there was no cell-surface staining of HA–Glut4–
GFP with anti-HA, whereas insulin treatment produced a strong
signal. Co-transfection of cells with wild-type Exo70 significantly
increased the cell-surface staining of HA–Glut4–GFP, as detected by
anti-HA antibodies, consistent with the increase in glucose trans-
port produced by overexpression of the protein. By contrast, co-
transfection of cells with the amino-terminal fragment of Exo70
completely blocked the appearance of HA–Glut4–GFP at the cell
surface (Fig. 4c, d), indicating that Exo70 might have a crucial role
in the membrane targeting of Glut4. An inhibitory mutant of TC10
also blocked the cell-surface exposure of exofacial tagged Glut4
(Supplementary Fig. 2).
The translocation of the insulin-responsive glucose transporter
Glut4 from intracellular membranes to the cell surface is likely to
involve numerous steps, typical of vesicular transport in other
systems. These may include mechanisms for the tethering of the
vesicle to target membranes, where it can come into contact with the
docking and fusion machinery. For many exocytotic processes, this
step is mediated by the exocyst, an evolutionarily conserved octa-
meric complex that targets vesicles to specific sites of the plasma
membrane19. Data presented here suggest that the exocyst complex
assembles at the plasma membrane of fat cells in response to insulin,
through the association of Exo70 with activated TC10, and has a role
in the tethering of the Glut4 vesicle, where it can come into
proximity with the SNARE (SNAP receptor) complexes involved
in docking and fusion20,21. The Rab proteins, which are mammalian
homologues of the yeast exocyst component Sec4, might mediate
this tethering step. Rab4 has been found in Glut4 vesicles, and
translocates to the plasma membrane in response to insulin22–25.
Moreover, we have also shown that TC10 can interact with the
effector protein CIP4, which is required for Glut4 translocation26.
So, TC10 might engage multiple effectors that influence both Glut4
translocation and tethering of the vesicle at the plasma membrane.
This possibility is under investigation. A
Methods
Yeast two-hybrid screen
The cDNA encoding full-length human TC10(Q75L) was amplified by polymerase chain
reaction (PCR) using the plasmid pKH3-TC10(Q75L) (a gift from I. Macara, University of
Virginia, Charlottesville) as a template, and a yeast two-hybrid cDNA library derived from
3T3L1 adipocyte messenger RNA was screened as described previously26.
Expression constructs
To generate a mammalian expression vector, full-length Exo70 cDNA was subcloned into
the pCS2 vector. To construct deletion mutants, Exo70 cDNA was digested with NcoI and
religated, generating Exo70-N or Exo70-C mutants. For 1–99 or 100–384 mutants, Exo70
was PCR-amplified from pCS2-Exo70 using oligonucleotides containing EcoRI/XhoI
restriction sites, and subcloned into pCS2 at EcoRI/XhoI.
In vitro GST pull-down assay
GST or GST–Exo70 fusion proteins were expressed in the BL21(DE3) pLysS Escherichia
coli strain and purified. Cell lysates were prepared for immunoprecipitation as described
below, and incubated with either GST alone or GST–Exo70 bound to glutathione-
Sepharose beads (Amersham Pharmacia) for 2 h at 4 8C. For GTP-binding experiments,
cell lysates were loaded in vitro with either 1 mM GDP or 100 mM GTPgS for 30 min at
37 8C before incubating with GST fusion proteins27. The beads were washed five times with
lysis buffer, resuspended in sample buffer, subjected to SDS–polyacrylamide gel
electrophoresis (SDS–PAGE), and analysed by immunoblotting with anti-myc
monoclonal antibody or polyclonal antibody (Santa Cruz Biotechnology) or anti-HA
monoclonal antibody (Santa Cruz Biotechnology).
Immunoprecipitation and immunoblotting
Cell lysates were prepared as described using 1% Triton X-100 (ref. 4). Lysates were then
incubated with the indicated antibodies for 2 h at 4 8C. The immune complexes were
precipitated with protein A or G agarose (Amersham Pharmacia) for 1 h at 4 8C, washed
extensively with lysis buffer, resolved in 10–20% gradient SDS–PAGE, and analysed by
immunoblotting. All immunoblots were developed by enhanced chemiluminesence
(Amersham Pharmacia). Anti-Sec6 (9H5) and Sec8 (2E9) monoclonal antibodies were
obtained from Calbiochem, and anti-caveolin-1 polyclonal antibody was obtained from
Transduction Laboratories.
Immunofluorescence microscopy
For immunofluorescence studies, electroporated cells were processed as described17. To
detect myc–Exo70, cells were stained with anti-myc monoclonal antibody or polyclonal
antibody (Santa Cruz Biotechnology). To detect HA–TC10, cells were stained with anti-
HA monoclonal antibody (Santa Cruz Biotechnology). After incubation with primary
antibodies, cells were incubated with Alexa488 or Alexa594 goat anti-mouse or anti-rabbit
immunoglobulin (IgG), obtained from Molecular Probes. Images were captured by using
an Olympus FV300 confocal laser scanning microscope.
Assays of Glut4–eGFP translocation and HA–Glut4–GFP
Glut4–eGFP translocation assays were performed as described28. The HA–Glut4–GFP
construct was a gift from S. W. Cushman (National Institutes of Health, Maryland). The
method was followed as described previously18.
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Transcription in eukaryotic cells has been described as quantal1,
with pulses of messenger RNA produced in a probabilistic
manner2,3. This description reflects the inherently stochastic
nature4–9 of gene expression, known to be a major factor in
the heterogeneous response of individual cells within a clonal
population to an inducing stimulus10–16. Here we show in
Saccharomyces cerevisiae that stochasticity (noise) arising
from transcription contributes significantly to the level of hetero-
geneity within a eukaryotic clonal population, in contrast to
observations in prokaryotes15, and that such noise can be modu-
lated at the translational level. We use a stochastic model of
transcription initiation specific to eukaryotes to show that
pulsatile mRNA production, through reinitiation, is crucial for
the dependence of noise on transcriptional efficiency, highlight-
ing a key difference between eukaryotic and prokaryotic sources
of noise. Furthermore, we explore the propagation of noise in a
gene cascade network and demonstrate experimentally that
increased noise in the transcription of a regulatory protein
leads to increased cell–cell variability in the target gene output,
resulting in prolonged bistable expression states. This result has
implications for the role of noise in phenotypic variation and
cellular differentiation.
To explore the effects of transcriptional variation and control on
the level of noise in eukaryotic gene expression, we used both native
and artificial modes of transcriptional regulation in the yeast GAL1
promoter (Fig. 1a). In its natural context, the GAL1 promoter is
activated in response to galactose (in the absence of preferentially
metabolized glucose) through an upstream activation sequence
(UASG) composed of multiple binding sites for the transcriptional
activator Gal4p. Like many eukaryotic activators17, Gal4p acts by
recruiting protein complexes involved in chromatin remodelling
and the ordered assembly of a transcription preinitiation com-
plex18,19. Because Gal4p is a galactose-dependent transcriptional
activator, activation-based expression from the GAL1 promoter is
effectively modulated with galactose. As a second mode of tran-
scriptional control, distinct from the native complexity of the
yeast galactose-utilization pathway, we constructed an artificial,
Tet-responsive GAL1 promoter (PGAL1*) by inserting tandem tet
operators (2£tetO 2) downstream of the GAL1 TATA box. In con-
trast to Gal4p-mediated activation, bound Tet repressor (TetR)
might act by sterically hindering the assembly of the transcriptional
machinery, effectively repressing expression from PGAL1*. TetR-
mediated repression can be relieved by the addition of the chemical
inducer anhydrotetracycline (ATc), which binds directly to TetR.
Constitutive expression of TetR therefore allows rheostat-like con-
trol of PGAL1* transcriptional efficiency through the use of varying
levels of ATc. The gene encoding the yeast-enhanced green fluor-
escent protein (yEGFP) was expressed from PGAL1* as a quantifiable
reporter, and fluorescence histograms were obtained from flow
cytometric measurement of similarly sized cells containing chromo-
somally integrated, single genetic copies of each construct.
Transcription from PGAL1* is modulated over a broad dynamic
range by both native and artificial modes of regulation (Fig. 1b),
allowing a direct comparison between galactose- and ATc-mediated
Figure 1 Transcriptional control of PGAL1*. a, TetR, expressed from PGAL10*, represses
expression of yEGFP. Anhydrotetracycline (ATc) and galactose (GAL) are required to
induce yEGFP expression. Transcription terminators (TADH1, TCYC1) are indicated.
b, Dose–response curve of PGAL1* expressing yEGFP to ATc at full galactose induction
(2%; red points), and to galactose at full ATc induction (500 ng ml21; blue points). Broken
lines were obtained from stochastic simulations (Box 1). c, Transient response of cells
marked A and B in b, induced with 0.2% galactose and 40 ng ml21 ATc, respectively.
Histograms correspond to preinduction (black), and 150 min (blue), 290 min (red) and
440 min (green) after induction.
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